


# Novel Targets in Advanced NSCLC: Leveraging Emerging Biomarkers in an Evolving Treatment Landscape



Saturday, 21 October 2023 | 13:00–14:30 CEST

Málaga Auditorium, Hall 10, IFEMA MADRID, Madrid, Spain

## Faculty



**Prof. Silvia Novello**  
(Chair)

University of Turin,  
Turin, Italy



**Prof. Aleš Ryška**

Fingerland Department  
of Pathology,  
Hradec Králové,  
Czech Republic



**Dr. Ernest Nadal**

Catalan Institute of  
Oncology, L'Hospitalet,  
Barcelona, Spain

During this Industry Satellite Symposium, we will:

- Educate on the history and recent developments of antibody–drug conjugate (ADC) technology
- Raise awareness of emerging biomarkers in NSCLC
- Increase knowledge of the clinical development and recent clinical results of ADCs for advanced NSCLC

## Agenda

Time (CEST)	Session	Faculty
13:00–13:05	Welcome and Introduction	Prof. Silvia Novello (Chair)
13:05–13:25	Treatment in Advanced NSCLC: What Have We Learned and Where Are We Headed?	Prof. Silvia Novello
13:25–13:45	Tailor-Made: Guiding Treatment Choice with Emerging Biomarkers	Prof. Aleš Ryška
13:45–14:05	What Does the Future Hold? Clinical Update on Antibody–Drug Conjugates in Advanced NSCLC	Dr. Ernest Nadal
14:05–14:30	Group Discussion	All faculty

This symposium is intended for healthcare professionals only.

This Industry Sponsored Symposium is organized and sponsored by Sanofi on the occasion of ESMO 2023 (20–24 October 2023). This is not a CME program. This Industry Sponsored Symposium is organized and sponsored by Sanofi and will include discussion of investigational products and products that may not be approved by the regulatory agency in your own country. The discussion is provided for medical and scientific purpose only. Viewers are cautioned to use their own professional judgment and consult the primary references, full prescribing information and/or any other appropriate sources prior to making clinical judgment for individual patients based on the content of the discussion.

MAT-GLB-2303194-V2.0; Date of approval: July 2023